Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

Gifting allows recipients to access the article for free. AbbVie Inc. rose the most in just over four years after it forecast 2025 earnings above Wall Street’s average expectation as two key ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

AbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average ...

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...